BRIEF-U.S. FDA Says If There Is Emergence Of Sars-Cov-2 Variant(S) In U.S. Moderately/ Fully Resistant To Current Vaccines,It May Be Necessary To Tailor Vaccines

* U.S. FDA-IF THERE IS EMERGENCE OF SARS-COV-2 VARIANT(S) IN U.S. MODERATELY/ FULLY RESISTANT TO CURRENT VACCINES,IT MAY BE NECESSARY TO TAILOR VACCINES

* FDA - EXPECTS MANUFACTURING INFORMATION WILL REMAIN GENERALLY SAME FOR AUTHORIZED VACCINE, A MODIFIED VACCINE CANDIDATE FROM SAME MANUFACTURER * FDA - MANUFACTURERS ALSO ENCOURAGED TO STUDY MODIFIED VACCINE IN BOTH NON-VACCINATED AND IN INDIVIDUALS PREVIOUSLY VACCINATED WITH AUTHORIZED VACCINE

* FDA -FURTHER DISCUSSIONS WILL BE NECESSARY TO DECIDE WHETHER IN FUTURE MODIFIED COVID19 VACCINES MAY BE AUTHORIZED WITHOUT NEED FOR CLINICAL STUDIES Source text : [ID:https://bit.ly/3dBtt0x] Further company coverage: [ ]